



Surgical Treatments for Glaucoma

Effective: October 1, 2026

Next Review: May 2027

Last Review: September 2026

IMPORTANT REMINDER

Medical Policies are developed to provide guidance for members and providers regarding coverage in accordance with contract terms. Benefit determinations are based in all cases on the applicable contract language. To the extent there may be any conflict between the Medical Policy and contract language, the contract language takes precedence.

PLEASE NOTE: Contracts exclude from coverage, among other things, services or procedures that are considered investigational or cosmetic. Providers may bill members for services or procedures that are considered investigational or cosmetic. Providers are encouraged to inform members before rendering such services that the members are likely to be financially responsible for the cost of these services.

DESCRIPTION

Glaucoma is usually caused by fluid build-up in the eye, which leads to optic nerve damage. Various minimally invasive techniques are available to treat glaucoma, including excimer laser trabeculostomy (also known as excimer laser trabeculotomy), femtosecond laser trabeculotomy, transcliliary fistulization, minimally invasive micro sclerostomy or trabeculostomy, and travoprost drug eluting ocular implants.

MEDICAL POLICY CRITERIA

Note: This policy does *not* address other procedures treating glaucoma (e.g., laser trabeculoplasty, trabeculectomy, aqueous stents or shunts).

The following devices and procedures for treatment of glaucoma are considered **investigational**:

- A. Excimer laser trabeculostomy or trabeculotomy
- B. Femtosecond laser trabeculotomy
- C. Transcliliary fistulization
- D. Minimally invasive micro sclerostomy or trabeculostomy

- E. Travoprost drug eluting ocular implants (e.g. iDose®TR)
- F. Scleral allograft-reinforced cyclodialysis

NOTE: A summary of the supporting rationale for the policy criteria is at the end of the policy.

CROSS REFERENCES

1. [Optical Coherence Tomography \(OCT\) of the Anterior Eye Segment](#), Medicine, Policy No. 133

BACKGROUND

GLAUCOMA SURGERY

Glaucoma is characterized by elevated intraocular pressure (IOP), which results in visual field loss and irreversible blindness if left untreated. In the primary (conventional) outflow pathway from the eye, aqueous humor passes through the trabecular meshwork (TM), enters a space lined with endothelial cells (Schlemm canal), drains into collector channels, and then into the aqueous veins. Increases in resistance in the trabecular meshwork and/or the inner wall of the Schlemm canal can disrupt the balance of aqueous humor inflow and outflow, resulting in an increase in IOP and glaucoma risk. Surgical procedures for glaucoma aim to reduce IOP resulting from impaired aqueous humor drainage in the trabecular meshwork and/or Schlemm's canal. These procedures may be indicated where medical therapy has failed to adequately control the IOP.

PRIMARY OPEN ANGLE GLAUCOMA TREATMENTS

Drug Therapy to Control IOP

Examples of drugs that may be prescribed include, but are not limited to, alpha-agonist, beta blockers, carbonic-anhydrase inhibitors, miotic agents and prostaglandin analogs.

Surgical Care

Laser Trabeculoplasty

A laser is used to burn small areas of the trabecular meshwork (where normal drainage of the eye occurs) to increase aqueous fluid outflow, thereby lowering IOP.

Incisional or Filtering Surgery (trabeculectomy or drainage implants)

Trabeculectomy (guarded filtration surgery) is a commonly performed surgical procedure for lowering IOP in glaucoma where medications cannot adequately control the pressure. In trabeculectomy, a fistula is created under a scleral flap and in the trabecular meshwork and adjacent structures to allow drainage of aqueous humor from the anterior chamber into a subconjunctival filtering bleb. However, trabeculectomy is associated with significant complications (e.g., leaks or bleb-related endophthalmitis) and long-term failure; therefore, other surgical interventions that aim to facilitate drainage of aqueous humor and reduce IOP have been developed, including aqueous shunts, micro-stents, and laser surgeries, such as selective laser trabeculoplasty and iridotomy.

Excimer laser trabeculostomy/trabeculotomy (ELT) and femtosecond laser trabeculotomy (FLT) are techniques that use lasers to create channels through the TM and into the Schlemm's canal. ELT requires a corneal incision and uses a 308-nm xenon chloride excimer laser in combination with a fiber optic delivery system to produce 200-µm trabeculostomy openings.^[1] FLT uses laser pulses through the cornea and across the anterior chamber to create channels through the trabecular meshwork and does not require corneal incision.

Cycloablation

This technique is also known as ablation of the ciliary body but is usually considered a last resort option due to the permanent destruction of the ciliary body.

Transciliary Fistulization (Transciliary Filtration, Singh Filtration)

Transciliary fistulization for the treatment of glaucoma is an approach to filtering surgery. A thermocauterization device called the Fugo Blade is used to create a plasma-ablated pore or filter track from the sclera through the ciliary body to allow aqueous fluid to ooze into the subconjunctival lymphatics from the posterior chamber (behind the iris) of the eye. Plasma ablation with the Fugo Blade allows the highly vascular ciliary body to be penetrated with little or no bleeding. Aqueous fluid drains from the posterior chamber of the eye (in contrast to conventional filtering surgeries in which aqueous fluid is filtered from the anterior chamber).

Minimally Invasive Micro Sclerostomy or Trabeculostomy

Minimally invasive micro sclerostomy (MIMS) is an ab interno stentless, subconjunctival filtration procedure used to create a sclerocorneal drainage channel for reduction of IOP. The MIMS surgical system by Sanoculis is inserted through a small incision to make a permanent drainage tunnel, allowing extra fluid to continuously flow out of the eye and lower eye pressure.

Scleral Allograft-Reinforced Cyclodialysis

The Alloflo™ Uveo procedure is a minimally invasive, ab-interno glaucoma surgery that targets the uveoscleral pathway via a surgically constructed cyclodialysis cleft to allow for the insertion of a biologic allograft spacer (human donor scleral tissue).^[2] A cyclodialysis cleft is created by separating the ciliary body from the scleral wall, establishing an internal drainage pathway that increases fluid outflow. Following the cleft creation, the Alloflo allograft bioscaffold is inserted into the cleft using the CycloPen®/AlloSert™ Uveo implantation system.^[3] The allograft functions as a spacer that reinforces the scleral wall, maintains the cyclodialysis cleft, and thereby supports and sustains uveoscleral outflow and lowering IOP.

Drug Eluting Ocular Implants

A variety of sustained-release drug eluting ocular implants are being developed as alternatives to topical delivery of IOP-lowering medications requiring daily dosing. These include travoprost (a prostaglandin analog) eluting intracameral implants (e.g., iDose®TR).

REGULATORY STATUS

There are currently no ELT, FLT, or MIMS devices that are approved by the U.S Food and Drug Administration (FDA). The ExTra ELT laser platform and MIMS system are available in Europe.

The Fugo Blade (Medisurg Ltd.) received the FDA 510(k) approval in October 2004 for sclerostomy for the treatment of primary open-angle glaucoma where maximum tolerated medical therapy and trabeculoplasty have failed.

The AlloSert Uveo (previously known as CycloPen) (Iantrek, Inc.) was reported to the FDA as Class I ophthalmic cannulas.^[4] This device listing pertains to the surgical instrumentation and should not be interpreted as FDA approval or clearance of the AlloFlo allograft implant or the cyclodialysis reinforcement procedure itself.

The iDose®TR (Glaukos) was granted a New Drug Application (NDA) approval from the FDA in December 2023 (NDA# 218010).^[5] The iDose TR is indicated for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension. The iDose®TR contains 75 mcg of travoprost pre-loaded in a single-dose inserter which is administered intracamerally through a small, clear corneal incision and is anchored into the sclera at the iridocorneal angle. The iDose®TR should not be readministered to an eye that received a prior iDose®TR. The iDose®TR (travoprost intracameral implant) is contraindicated in patients with:

- active or suspected ocular or periocular infections.
- corneal Endothelial Dystrophy (e.g., Fuch's Dystrophy, corneal guttatae).
- prior corneal transplantation, or endothelial cell transplants (e.g., Descemet's Stripping Automated Endothelial Keratoplasty [DSAEK]).
- hypersensitivity to travoprost or to any other components of the product.

EVIDENCE SUMMARY

EXCIMER LASER TRABECULOSTOMY

Systematic Reviews

Durr (2020) published a review of the evidence for ELT that included eight published studies: one randomized controlled trial (RCT), two prospective case series, and five retrospective case series, as well as two studies that were not yet published: a retrospective observational study that has since been published and a prospective observational study that has not.^[1] The RCT, published by Babighian (2010), compared ELT (n=15) to selective laser trabeculoplasty (SLT, n=15) and reported complete and qualified success rates that were not significantly different between groups at two years (53% for ELT vs. 40% for SLT, $p=0.35$, and 33.3% for ELT vs. 26.6% for SLT, respectively).^[6] The review did not evaluate the quality of the included studies. The authors noted the RCT's small sample size and concluded that while "current available evidence show an IOP-lowering effect from ELT alone or in combination with cataract surgery with encouraging results across different studies and patient populations, [...] more studies are needed to better characterize ELT and further substantiate these promising results."

A systematic review and meta-analysis by Lavia (2017) assessed the evidence for different minimally-invasive glaucoma surgeries (MIGS) for open angle glaucoma.^[7] The review included nine RCTs and 21 case series that evaluated a number of procedures and devices, including ELT. Only studies with at least 12 months of follow-up were included, and the primary outcome was change in both IOP and the use of glaucoma medications at 12 months. The studies of ELT included in the review were the RCT by Babighian (2010)^[6] and two observational studies.^[8, 9] The RCT was judged to be at low risk of bias for all domains except allocation concealment, which was at unclear risk, while the observational studies were both judged to have serious risk of bias in at least one domain. The meta-analysis indicated that

MIGS were associated with a decrease of IOP and a reduction of glaucoma medications and that these procedures had a low complication rate, but it also noted substantial heterogeneity between studies.

Randomized Controlled Trials

No additional RCTs beyond the trial included in the reviews above were identified.

Nonrandomized Studies

No nonrandomized controlled trials published since the systematic reviews above were identified.

A retrospective review of combined ELT and phacoemulsification procedures performed at a clinic in Spain was published by Papa-Vettorazzi (2023).^[10] One-year follow up data from 37 eyes showed a reduction in IOP from 17.76 ± 4.88 mmHg to 15.35 ± 3.10 mmHg. The authors reported that the procedure was a complete success in 17.7% of eyes and a qualified success in 54.8%.

Berlin (2022) published a retrospective review of ELT procedures performed at a single institution.^[11] This included 164 eyes, 90 treated with ELT alone and 74 treated with a combination of ELT and phacoemulsification. IOP went from 22.17 ± 7.0 mm Hg to 16.84 ± 5.2 mm Hg at one year ($n = 69$) in the ELT-only group, and in the 19 eyes with eight-year follow-up data, this reduction was maintained. Similar results were seen in the combination treatment group.

A study by Deubel (2021) included 87 patients that underwent ELT without cataract surgery.^[12] There was an IOP reduction of almost 30% after the first year and almost 24% after two years. IOP generally increased from the post-operative result through three years. After a median follow-up of 656 days, 66% of these patients did not require another IOP-lowering intervention. There was no reduction in the number of glaucoma medications at the final follow-up.

FEMTOSECOND LASER TRABECULOTOMY

Systematic Reviews

No systematic reviews were identified on femtosecond laser trabeculotomy.

Randomized Controlled Trials

No RCTs were identified on femtosecond laser trabeculotomy.

Nonrandomized Studies

Nagy (2023) published the results of a first-in-human safety study of femtosecond laser image-guided trabeculotomy in 12 patients (18 eyes).^[13] At 24 months following the procedure, the mean IOP was reduced by 34.6% from 22.3 ± 5.5 to 14.5 ± 2.6 mmHg ($p < 5e^{-5}$). No serious adverse events were reported.

TRANSCILIARY FISTULIZATION

Systematic Reviews

A systematic review by Lavia (2017), discussed earlier, also included transcliliary fistulization.^[7] However, there were no RCTs that evaluated the Fugo Blade and none of the case studies met the inclusion criteria for follow-up time.

Randomized Controlled Trials

No RCTs were identified on transcliliary fistulization for the treatment of glaucoma.

Nonrandomized Studies

Data concerning transcliliary fistulization consists of case series and nonrandomized comparative studies. The nonrandomized studies have limitations including a nonrandomized design, lack of appropriate comparator groups, small sample sizes, short term follow-up, and/or significant loss of patients at follow-up.^[14-16]

MINIMALLY INVASIVE MICRO SCLEROSTOMY OR TRABECULOSTOMY

Systematic Reviews

No systematic reviews were identified on minimally invasive micro sclerostomy or trabeculostomy.

Randomized Controlled Trials

No RCTs were identified on minimally invasive micro sclerostomy or trabeculostomy.

Nonrandomized Studies

The evidence is limited to two single-arm prospective trials.^[17, 18] Both studies have limitations including nonrandomized design, lack of appropriate comparator groups, relatively small sample sizes, and iris clogging complications requiring additional interventions in a subset of patients. The larger study by Voskanan (2024) performed 120 minimally invasive micro sclerostomy in patients with uncontrolled glaucoma. The one-year follow-up included 93 patients and found qualified success of 82.1% (95% confidence interval [CI]: 72.9% to 89.2%) of the patients and complete success in 70.5% (60.3 to 79.4%). 60% (95% CI: 49.4% to 69.9%) of the patients achieved maximum IOP level of 14 mmHg or at least 30% reduction in IOP.

SCLERAL ALLOGRAFT-REINFORCED CYCLODIALYSIS

Systematic Reviews

No systematic reviews were identified on scleral allograft-reinforced cyclodialysis.

Randomized Control Trials

No RCTs were identified on scleral allograft-reinforced cyclodialysis.

Nonrandomized Studies

In this manufacturer-funded study, Barber (2025) evaluated the clinical outcomes of a bio-interventional uveoscleral outflow enhancement surgery with an allograft-reinforced cyclodialysis through a 12-month follow-up period.^[19] Fifty-one eyes with a mean baseline medicated intraocular pressure (IOP) of 25.7 ± 4.4 mmHg underwent the procedure, with 83% also receiving cataract surgery. At 12 months, mean IOP was significantly reduced to $15.4 \pm$

4.5 mmHg ($p < 0.01$), representing an approximately 40% reduction, while IOP-lowering medication use decreased by 42%. Additionally, 86.7% of subjects achieved an IOP below 18 mmHg on the same or fewer medications. In the standalone cyclodialysis cohort that did not undergo adjunct phacoemulsification ($n = 9$), mean medicated IOP decreased by 30%, from 29.3 ± 6.4 mmHg at baseline to 20.6 ± 6.7 mmHg at 12 months ($p = 0.035$), with an additional reduction in medication burden. The scleral allograft scaffold remained stable through 12 months without migration or degradation, and no serious vision-threatening adverse events were reported. The authors concluded that scleral allograft-reinforced cyclodialysis is a safe and durable approach for enhancing uveoscleral outflow and achieving sustained IOP reduction in POAG patients who are inadequate responders to medical therapy.

One study evaluated the safety and effectiveness of scleral allograft-reinforced cyclodialysis performed in conjunction with cataract surgery for patients with open-angle glaucoma (OAG) over a 2 year follow-up period. In the initial 12-month prospective case series of 117 eyes, mean medicated intraocular pressure (IOP) decreased by 27.1% from baseline, with a 39.7% reduction among eyes with baseline IOP >21 mmHg, in addition to a reduction in glaucoma medication use (Ianchulev 2024).^[2] At one year, 81.9% of eyes achieved an IOP ≤ 18 mmHg without an increase in medications, and only 3.2% required additional glaucoma surgery. The procedure was associated with minimal intraoperative bleeding, few postoperative adverse events, and no significant safety concerns. Longer-term follow-up in a subset of 31 eyes demonstrated sustained efficacy through 24 months, with 74% of eyes achieving at least a 20% IOP reduction on the same or fewer medications and a mean IOP reduction of 34% from baseline (Calvo 2025).^[20] Mean medicated IOP decreased from 21.9 ± 4.9 mmHg on 1.22 medications at baseline to 12.6 ± 2.6 mmHg on 0.55 medications at 12 months, with the authors reporting continued safety and no serious ocular adverse events throughout follow-up. Overall, the findings suggest that scleral allograft-reinforced cyclodialysis may provide durable enhancement of uveoscleral outflow, resulting in sustained IOP reduction and decreased medication burden when performed at the time of cataract surgery in patients with OAG. However, the study's findings are limited by the prospective, single-arm, uncontrolled study design, relatively small sample size and limited long-term follow-up. Additional larger, controlled studies with longer follow-ups are needed to confirm durability and further compare outcomes with other minimally invasive glaucoma surgeries.

IDOSE®TR (TRAVOPROST INTRACAMERAL IMPLANT)

Systematic Reviews

No systematic reviews were identified on travoprost intracameral implant.

Randomized Controlled Trials

Sarkisian (2024) published a prospective, multicenter, randomized, double-masked pivotal phase 3 trial evaluating the efficacy and safety of the travoprost intracameral slow-eluting (SE) implant (the intended commercial product) and fast-eluting (FE) implant (included primarily for masking purposes) compared to twice-daily 0.5% timolol ophthalmic solution in patients with open-angle glaucoma or ocular hypertension.^[21] The primary efficacy endpoints were the mean change from baseline IOP at 8 A.M. and 10 A.M. at day 10, week 6, and month 3. Non-inferiority was achieved if the upper 95% CI on the difference in IOP change from baseline (implant minus timolol) was < 1.5 mmHg at all six timepoints and < 1 mmHg at three or more timepoints. The results showed that the SE implant was non-inferior to timolol eye drops in IOP lowering over 12 months, with a significantly greater proportion of patients in the SE implant

group (83.5%) compared to the timolol group (23.9%) on fewer topical glaucoma medications at month 12 compared to screening ($p<0.0001$). Similarly, the FE implant was non-inferior to timolol over nine months, with 78.7% of patients in the FE implant group on fewer topical glaucoma medications at month 12 compared to screening ($p<0.0001$). Adverse effects were mostly mild, with treatment emergent adverse events reported in 39.5% of patients in the SE implant group, 34.0% in the FE implant group, and 20.1% in the timolol group. Study limitations include lack of long-term follow-up, the sham administration procedure for the timolol group and possible conflict of interest.

Sarkisian (2024) published the results of one of the phase three trials to evaluate the safety and IOP-lowering efficacy of two models of the travoprost intraocular implant (FE and SE).^[22] The primary outcome was the mean change from baseline IOP in the study eye at 8 am and 10 am, at each of day 10, week 6, and month 3. The travoprost intraocular implant (both FE and SE types) demonstrated robust IOP reduction over the 3-month primary efficacy evaluation period after a single administration. The mean IOP reduction from baseline over the six time points ranged from 6.6 to 8.4 mmHg for the FE implant group, from 6.6 to 8.5 mmHg for the SE implant group, and from 6.5 to 7.7 mmHg for the timolol group. The primary efficacy endpoint was met, with the upper limit of the 95% confidence interval of the difference between the implant groups and the timolol group being < 1 mmHg at all 6 time points, indicating noninferiority. Adverse events were reported in 21.5% of patients in the FE implant group, 27.2% in the SE implant group, and 10.8% in the timolol group, with the most common adverse events including iritis (FE implant, 0.5%; SE implant, 5.1%), ocular hyperemia (FE implant, 3.0%; SE implant, 2.6%), reduced visual acuity (FE implant, 1.0%; SE implant, 4.1%; timolol, 0.5%), and IOP increased (FE implant, 3.5%; SE implant, 2.6%; timolol, 2.1%). One serious eye adverse event occurred (endophthalmitis). The study's limitations include the short follow-up period of three months, use of a sham administration procedure for the timolol group and possible conflict of interest.

Bacharach (2024) published a post-hoc analysis study to compare the IOP treatment effects of the SE travoprost intracameral implant and topical prostaglandin analog (PGA) monotherapy in a subgroup subjects ($n = 133$) who were on prestudy PGA monotherapy prior to enrollment in two pivotal phase 3 trials.^[23] The primary efficacy endpoint was the IOP-lowering treatment effect. The subjects were analyzed for the IOP treatment effects of the pre-study topical PGA monotherapy and the in-study SE travoprost intracameral implant. The SE travoprost intracameral implant demonstrated a significantly greater IOP-lowering treatment effect (-7.07 mmHg) compared to pre-study topical PGA monotherapy (-5.76 mmHg), with a superiority margin of 1.31 mmHg (95% CI: -2.01 to 0.60 ; $p=0.0003$).

PRACTICE GUIDELINE SUMMARY

American Academy of Ophthalmology (AAO)

The 2020 American Academy of Ophthalmology Preferred Practice Patterns guidelines for primary open-angle glaucoma do not discuss excimer laser trabeculostomy/trabeculotomy, femtosecond laser trabeculotomy, transciliary fistulization, minimally invasive micro sclerostomy or trabeculostomy among the various surgery options.^[24] They recognize that adherence to topical eye-drops may be a barrier to optimal therapy, and notes that multiple drug delivery systems have been developed to address this issue, including Durysta®. These guidelines do not address the iDose®TR.

SUMMARY

There is not enough research to show that excimer laser trabeculostomy or trabeculotomy or femtosecond laser trabeculotomy can improve health outcomes for individuals with glaucoma. In addition, evidence-based clinical practice guidelines for glaucoma treatment do not discuss these procedures. Therefore, they are considered investigational.

There is not enough research to show that transcliliary fistulization improves health outcomes for individuals with glaucoma. No clinical practice guidelines recommend transcliliary fistulization for the treatment of glaucoma. Therefore, transcliliary fistulization for the treatment of glaucoma is considered investigational.

There is not enough research to show that minimally invasive micro sclerostomy or trabeculostomy improve health outcomes for individuals with glaucoma. No clinical practice guidelines recommend minimally invasive micro sclerostomy or trabeculostomy for the treatment of glaucoma. Therefore, minimally invasive micro sclerostomy or trabeculostomy for the treatment of glaucoma is considered investigational. There is not enough research to show that travoprost drug eluting ocular implants (e.g. iDose®TR) improve health outcomes when compared to the standard of care. No clinical guidelines based on research recommend travoprost drug eluting ocular implants (e.g. iDose®TR) for the treatment of open angle glaucoma. Therefore, travoprost drug eluting ocular implants (e.g. iDose®TR) are considered investigational for treatment of open angle glaucoma.

There is not enough research to show scleral allograft-reinforced cyclodialysis improves health outcomes for individuals with glaucoma. No clinical practice guidelines recommend allograft-reinforced cyclodialysis for the treatment of glaucoma. Therefore, allograft-reinforced cyclodialysis for the treatment of glaucoma is considered investigational.

REFERENCES

1. Durr GM, Töteberg-Harms M, Lewis R, et al. Current review of Excimer laser Trabeculostomy. *Eye Vis (Lond)*. 2020;7:24. PMID: 32391398
2. Ianchulev T, Weinreb RN, Calvo EA, et al. Bio-Interventional Cyclodialysis and Allograft Scleral Reinforcement for Uveoscleral Outflow Enhancement in Open-Angle Glaucoma Patients: One-Year Clinical Outcomes. *Clin Ophthalmol*. 2024;18:3605-14. PMID: 39659876
3. Iantrek - Alloflo Uveo. [cited 09/09/2026 website]. 'Available from:' <https://www.iantrekmed.com/alloflo>.
4. U.S. Food and Drug Administration (FDA) Establishment Registration and Device Listing for Cyclophen. [cited 09/09/2026]. 'Available from:' <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfr/rl.cfm?lid=717088&lpcd=HMX>.
5. U.S. Food and Drug Administration (FDA) Prescribing information for iDose TR. [cited 7/10/2026]. 'Available from:' https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218010s000lbl.pdf.
6. Babighian S, Caretti L, Tavalato M, et al. Excimer laser trabeculotomy vs 180 degrees selective laser trabeculoplasty in primary open-angle glaucoma. A 2-year randomized, controlled trial. *Eye (Lond)*. 2010;24(4):632-8. PMID: 19590523

7. Lavia C, Dallorto L, Maule M, et al. Minimally-invasive glaucoma surgeries (MIGS) for open angle glaucoma: A systematic review and meta-analysis. *PLoS One*. 2017;12(8):e0183142. PMID: 28850575
8. Babighian S, Rapizzi E, Galan A. Efficacy and safety of ab interno excimer laser trabeculotomy in primary open-angle glaucoma: two years of follow-up. *Ophthalmologica*. 2006;220(5):285-90. PMID: 16954703
9. Töteberg-Harms M, Hanson JV, Funk J. Cataract surgery combined with excimer laser trabeculotomy to lower intraocular pressure: effectiveness dependent on preoperative IOP. *BMC Ophthalmol*. 2013;13:24. PMID: 23799932
10. Papa-Vettorazzi R, Pascual L, Moura-Coelho N, et al. Real life experience following combined excimer laser trabeculostomy and phacoemulsification in eyes with ocular hypertension or mild glaucoma and cataract. *Arch Soc Esp Oftalmol (Engl Ed)*. 2023;98(9):521-27. PMID: 37364679
11. Berlin MS, Shakibkhou J, Tilakaratna N, et al. Eight-year follow-up of excimer laser trabeculostomy alone and combined with phacoemulsification in patients with open-angle glaucoma. *J Cataract Refract Surg*. 2022;48(7):838-43. PMID: 34732680
12. Deubel C, Böhringer D, Anton A, et al. Long-term follow-up of intraocular pressure and pressure-lowering medication in patients following Excimer laser trabeculotomy. *Graefes Arch Clin Exp Ophthalmol*. 2021;259(4):957-62. PMID: 33289863
13. Nagy ZZ, Kranitz K, Ahmed IIK, et al. First-in-Human Safety Study of Femtosecond Laser Image-Guided Trabeculotomy for Glaucoma Treatment: 24-month Outcomes. *Ophthalmol Sci*. 2023;3(4):100313. PMID: 37363134
14. Dow CT, deVenecia G. Transciliary filtration (Singh filtration) with the Fugo plasma blade. *Ann Ophthalmol (Skokie)*. 2008;40(1):8-14. PMID: 18556974
15. Sinha R, Bali SJ, Kumar C, et al. Results of cataract surgery and plasma ablation posterior capsulotomy in anterior persistent hyperplastic primary vitreous. *Middle East Afr J Ophthalmol*. 2013;20(3):217-20. PMID: 24014984
16. Singh D, Singh K. Transciliary filtration using the Fugo Blade. *Ann Ophthalmol*. 2002;34(3):183-7. PMID: No PMID Entry
17. Geffen N, Kumar DA, Barayev E, et al. Minimally Invasive Micro Sclerostomy (MIMS) Procedure: A Novel Glaucoma Filtration Procedure. *J Glaucoma*. 2022;31(3):191-200. PMID: 34731867
18. Voskanyan L, Ahmed IIK, Gershoni A, et al. Minimally invasive micro sclerostomy (MIMS) procedure in the treatment of open-angle glaucoma. *BMC Ophthalmol*. 2024;24(1):122. PMID: 38494493
19. Barber K, Flowers B, Patterson M, et al. Bio-interventional uveoscleral outflow enhancement in patients with medically uncontrolled primary open-angle glaucoma: 1-year results of allograft-reinforced cyclodialysis. *Ther Adv Ophthalmol*. 2025;17:25158414251362010. PMID: 40799662
20. Calvo E, De Francesco T, Vera L, et al. Bio-interventional Uveoscleral Outflow Enhancement Surgery for Primary Open-Angle Glaucoma: 2-Year Results of Cyclodialysis with Scleral Allograft Reinforcement. *Ophthalmol Sci*. 2025;5(4):100727. PMID: 40230881
21. Sarkisian SR, Ang RE, Lee AM, et al. Travoprost Intracameral Implant for Open-Angle Glaucoma or Ocular Hypertension: 12-Month Results of a Randomized, Double-Masked Trial. *Ophthalmol Ther*. 2024;13(4):995-1014. PMID: 38345710
22. Sarkisian SR, Jr., Ang RE, Lee AM, et al. Phase 3 Randomized Clinical Trial of the Safety and Efficacy of Travoprost Intraocular Implant in Patients with Open-Angle

Glaucoma or Ocular Hypertension. *Ophthalmology*. 2024;131(9):1021-32. PMID: 38423216

23. Bacharach J, Doan LV, Stephens KG, et al. Travoprost Intracameral Implant Demonstrates Superior IOP Lowering Versus Topical Prostaglandin Analog Monotherapy in Patients with Open-Angle Glaucoma or Ocular Hypertension. *Ophthalmol Ther*. 2024;13(9):2357-67. PMID: 38985408
24. American Academy of Ophthalmology Preferred Practice Pattern Guidelines. Primary Open-Angle Glaucoma. AAO PPP Glaucoma Committee. [cited 7/10/2026]. 'Available from:' [https://www.aaojournal.org/article/S0161-6420\(20\)31024-1/fulltext](https://www.aaojournal.org/article/S0161-6420(20)31024-1/fulltext).

CODES

Codes	Number	Description
CPT	0621T	Trabeculostomy ab interno by laser
	0622T	Trabeculostomy ab interno by laser; with use of ophthalmic endoscope
	0660T	Implantation of anterior segment intraocular nonbiodegradable drug-eluting system, internal approach
	0661T	Removal and reimplantation of anterior segment intraocular nonbiodegradable drug eluting implant
	0730T	Trabeculotomy by laser, including optical coherence tomography (OCT) guidance
	1012T	Motorized ab interno trephination of sclera (sclerostomy), or trabecular meshwork (trabeculostomy), 1 or more, including injection of antifibrotic agents, when performed
	1084T	Implantation of scaffolding allograft to reinforce the suprachoroidal space
	66999	Unlisted procedure, anterior segment of eye
HCPCS	J7355	Injection, travoprost, intracameral implant, 1 mcg

Date of Origin: May 2022